3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
Breast
1
Conditions
Stomach Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Lung Neoplasms
1
Head and Neck Squamous Cell Cancer
1
Head and Neck Neoplasms
1
Esophageal Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Hepatocellular
1
Breast Neoplasms
1
Interventions
pembrolizumab
20
Docetaxel
8
Carboplatin
8
Fluorouracil
6
Cisplatin
6
Nivolumab
5
fludarabine
4
Trastuzumab
4
Paclitaxel
4
Magnetic Resonance Spectroscopy
4
Gemcitabine
4
Cyclophosphamide
4
Biopsy
4
Bevacizumab
4
fludarabine phosphate
3
durvalumab
3
atezolizumab
3
Taxes
3
Radiotherapy
3
Polymerase Chain Reaction
3
Gene Expression Profiling
3
Capecitabine
3
Albumin-Bound Paclitaxel
3
ulixertinib
2
tisotumab vedotin
2
spartalizumab
2
belinostat
2
adavosertib
2
X-Rays
2
Vorinostat
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Esophageal Neoplasms
×
rocakinogene sifuplasmid
×
Head & Neck
×
Clear all
NCT02960594
2018-11-19
TRT-001
Inovio Pharmaceuticals
Phase 1
Completed
93 enrolled